52nd week of 2009 patent applcation highlights part 37 |
Patent application number | Title | Published |
20090317341 | Compositions for Lightening Skin Color - Skin lightening additives and skin lightening compositions having at least one of a heterosubstituted, saturated or unsaturated aliphatic acid are described. The compositions are suitable for topical application and may comprise 12-hydroxystearic acid, ricinoleic acid or both. | 2009-12-24 |
20090317342 | USE OF FLAVONOIDS - The present invention relates to the use of at least one flavonoid for odour improvement and/or odour stabilisation, and to corresponding compositions and the preparation thereof. | 2009-12-24 |
20090317343 | Personal Care Compositions Containing Silicone Elastomer Gels - Personal care compositions are disclosed containing a silicone elastomer from the reaction of an organohydrogen-siloxane having at least two SiH containing cyclosiloxane rings in its molecule, a compound having at least two aliphatic unsaturated groups in its molecule, and a hydrosilylation catalyst. | 2009-12-24 |
20090317344 | HIGH-WATER CONTENT LIPSTICK AND ITS PREPARATION - This invention describes a high water content lipstick and its preparation. This formula includes 1-10 wt % emulsifiers, 1-30 wt % water phase and 69-98 wt % oil components phase. Pigments, pearl agents, water soluble active ingredients can be introduced when required. Polyglyceryl fatty ester, fatty ester and silicone derivative are combined as the mixed emulsifier to form a water-in-oil pre emulsion and then add this pre emulsion into other oil components. This preparing method is easy to handle and can increase the water content effectively. The samples produced according to this invention are very stable in storage and usage: no coarse surface or air bubbles phenomena appear. As this kind of formula comprises water, the cost may be lowered compared with normal anhydrous formulas, moreover, water soluble active ingredients are also possible to be added, which will give the consumer a totally new feeling. The invention can be widely applied in lip care products. | 2009-12-24 |
20090317345 | Antiperspirant/Deodorant Gel Composition With Low Pouring Temperature - Solid stick antiperspirant and deodorant compositions containing both branched and linear N-acyl gelling agents along with dipropylene glycol are provided. Such compositions exhibit advantageous pouring temperatures below about 80° C. | 2009-12-24 |
20090317346 | DEODORANT AGENT - This invention relates to deodorant agents, which contain | 2009-12-24 |
20090317347 | Antiperspirant/Deodorant Compositions - A composition comprising a structuring agent for the composition comprising a partially hydrogenated soybean oil with a melting point of about 26 to about 38° C. in an amount of about 5% or less by weight: and at least one active chosen from antiperspirant actives and deodorant actives in an amount of about 0.5 to about 16% by weight of the composition on an active weight basis. The composition can be used as an antiperspirant and/or deodorant when applied to an axillary area of a person. | 2009-12-24 |
20090317348 | Production of structured hairstyles using a composition comprising reactive silicone compounds - The present invention relates to the treatment of human keratin fibres to obtain structured hairstyles, for example with structured locks, which consists in applying a composition comprising at least one compound X and Y, at least one of which is a silicone compound, these compounds furthermore being capable of reacting together via a hydrosilylation reaction, or via a condensation reaction, or via a crosslinking reaction in the presence of a peroxide. | 2009-12-24 |
20090317349 | Stabilized Hydrogen Peroxide Compositions and Methods - A hydrogen peroxide-containing composition comprising at least one antioxidant and at least one free radical scavenger operable to neutralize reactive oxygen species generated by the hydrogen peroxide and a method for stabilizing hydrogen peroxide containing compositions. | 2009-12-24 |
20090317350 | KERATIN FIBRE COATING COMPOSITION COMPRISING AN AQUEOUS PHASE AND A TACKIFYING RESIN - The present invention relates to a keratin fibre coating composition comprising an aqueous phase and at least one resin chosen from rosins, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, the said resin having a number-average molecular weight of less than or equal to 10 000, the said composition being capable of forming a film with a water resistance such that ΔL is less than or equal to −1. | 2009-12-24 |
20090317351 | CONCENTRATED BEVERAGE COMPOSITON FOR HAIR HEALTH CARE, METHOD OF MANUFACTURING THE CONCENTRATED BEVERAGE COMPOSITION AND NATURAL TEA COMPRISING THE SAME - Disclosed are a concentrated beverage composition for hair health care, a method of manufacturing the concentrated beverage composition, and a natural tea comprising the same. The concentrated beverage composition for hair health care comprises 100 parts by weight of water, 10 to 20 parts by weight of | 2009-12-24 |
20090317352 | HYPERPHOSPHATEMIA IN DOMESTIC ANIMALS: COMPOSITIONS AND METHODS OF TREATMENT - The present invention is generally related to the treatment of hyperphosphatemia in domestic animals. It is specifically directed to compositions containing phosphate binders that are palatable to domestic animals and methods using such compositions. In a composition aspect, the present invention provides a composition that includes: a rare earth compound (e.g., lanthanum oxycarbonate or lanthanum carbonate hydroxide), calcium salts (e.g, calcium carbonate or calcium acetate), aluminum salts (e.g., aluminum hydroxide or a hydrophilic exchange resin; and an ingredient of domestic animal food, wherein the ingredient is selected from a group consisting of chicken, beef, lamb, chicken meal or lamb meal, corn, rice, bone meal, fish meal, fish, egg product, beef, beef meal, corn gluten meal, poultry by-product meal, wheat flour, beef tallow, maple syrup, honey, apple, flaxseed, flaxseed meal, rice bran and germ, oats, barley, and wheat bran. | 2009-12-24 |
20090317353 | Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator - The present invention relates to compositions of cyanoacrylate monomer, a method of improving the viscosity and the curing speed with a single additive and a process of providing sterilized cyanoacrylate adhesive compositions for application in the medical field. | 2009-12-24 |
20090317354 | Composition for restoring damaged skin comprising a saccaride and povidone-iodine - The present invention relates to a composition for repairing injured skin containing a saccharide and povidone-iodine. The present invention has the following characteristics: suppresses time-dependent increase of consistency, it is easy to use, it is a soft preparation, and has superior applicability to a deep wounded lesion and a granulation tissue. The composition of the present invention contains 50 to 90% by weight of saccharide, 0.5 to 10% by weight of povidone-iodine, 0.1 to 20% by weight of water and 0.01 to 10% by weight of phospholipid. | 2009-12-24 |
20090317355 | ABUSE RESISTANT MELT EXTRUDED FORMULATION HAVING REDUCED ALCOHOL INTERACTION - The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse-resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. Most preferably, the dosage form includes verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release. | 2009-12-24 |
20090317356 | Composition and method for repelling mammals - A composition that first attracts then repels mammals, which is delivered via an easy-to-use open container, or on a transportable flat surface. The open container or transportable flat surface holding the composition may be placed near, in or on an object or area to be protected. The composition maintains its effectiveness over an extended period of time, in varying climates and weather conditions. | 2009-12-24 |
20090317357 | Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents - Methods for treating or preventing an autoimmune disease using agents that block the histamine H1 receptor are disclosed. H1 receptor-blocking agents useful in accordance with the methods provided herein include, for example, H1 antihistamines, particularly H1 antihistamines that do not substantially block the serotonin receptor. | 2009-12-24 |
20090317358 | CHIMERIC PROTEINS WITH CELL-TARGETING SPECIFICITY AND APOPTOSIS-INDUCING ACTIVITIES - The present invention relates to chimeric proteins with cell-targeting specificity and apoptosis-inducing activities. In particular, the invention is illustrated by a recombinant chimeric protein between human interleukin-2 (IL2) and Bax. The chimeric protein specifically targets IL2 receptor (IL2R)-expressing cells and induces cell-specific apoptosis. | 2009-12-24 |
20090317359 | 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AND METHODS OF THEIR USE AS INHIBITORS OF RAF KINASE - New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. | 2009-12-24 |
20090317360 | ANTI-VIRAL INHIBITORS AND METHODS OF USE - Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses. | 2009-12-24 |
20090317361 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT - Provided are imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. | 2009-12-24 |
20090317362 | USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION - The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer. | 2009-12-24 |
20090317363 | Cytokine Derivatives - The invention relates to polypeptides comprising an N-terminal portion and a C-terminal portion, wherein said N-terminal portion comprises the signature sequence QGP[P or L] and the amino acid sequence of said C-terminal portion is at least 70% identical to SEQ ID NO: 1, and uses thereof. | 2009-12-24 |
20090317364 | NOVEL COMPOSITIONS FOR PREVENTION AND TREATMENT OF MASTITIS AND METRITIS - A novel stable synergistic compositions used for the prevention and/or treatment of mastitis and metritis in mammals comprising a combination of therapeutically effective amount of | 2009-12-24 |
20090317365 | SYSTEMS AND METHODS FOR MAKING HEPATOCYTES FROM EXTRAHEPATIC SOMATIC STEM CELLS AND USE THEREOF - A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising oncostatin M to cause the differentiated cells to mature into hepatocytes, thereby producing a cell population that has morphological features of hepatocytes and at least four of the following characteristics: i) antibody-detectable expression of albumin; ii) real-time reverse transcriptase-polymerase chain reaction-detectable expression of α-fetoprotein, HNF-1α, HNF-3β, HNF-4, HNF-6, α1-antitrypsin, alkaline phosphatase, tryptophan 2,3-dioxygenase, tyrosine aminotransferase, cytochrome P450 family 2 subfamily E polypeptide 1, glutamine synthetase, and/or low density lipoprotein receptor; iii) urea secretion; iv) cytochrome p450 enzyme activity; v) glycogen storage; and vi) low density lipoprotein uptake. | 2009-12-24 |
20090317366 | METHOD FOR TREATING PROGRESSIVE NEURODEGENERATIVE DISORDERS - A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist. | 2009-12-24 |
20090317367 | METHODS OF PRODUCING PREADIPOCYTES AND INCREASING THE PROLIFERATION OF ADULT ADIPOSE STEM/PROGENITOR CELLS - The present invention describes preadipocytes and methods of differentiating macrophages into preadipocytes by co-culturing adipocytes and resident adipose tissue macrophages. Also described are methods of increasing the proliferative rate of adipose adult stem/progenitor cells. | 2009-12-24 |
20090317368 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides. | 2009-12-24 |
20090317369 | COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICRORNAS AND METHODS OF THEIR USE IN REPAIRING DAMAGED MYOCARDIUM - The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed. | 2009-12-24 |
20090317370 | Methods And Means For Protecting The Skin Against Pathogenic Microorganisms - Described are microorganisms which are, in a first aspect, able to to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications. | 2009-12-24 |
20090317371 | Method, Composition, and Device, for the Treatment of Amylase Malfunctions / Inactivity in Association with Saccharides (Mainly Polysaccharides) Based Diseases - Physiological protein and enzyme complex having active Trimethylglycine, active amylases, active lipases, and active proteases, of human (saliva enzymes), yeast, plant, fungi, and or microbial origin, preferably digestive enzyme complex such as, Trimethylglycine, 4-α-D-glucan glucanohydrolase; Exo-1,4-α-glucosidase; Beta-fructofuranosidase; Protease (3.0); Pectinase; Lipase; Cellulase; Lactase; Malt Diastase, or digestive enzyme complex containing proteins and enzymes for the treatment of high levels of saccharides and correction of amylases malfunctioning activity or inactivity in the body. The invention also relates to the production of pharmaceutical compositions suitable for such treatment. A preferred variant of the invention relates to use of this enzyme complex having Trimethylglycine, amylolytic, lipolytic, and proteolytic activity, especially salivary, gastric, pancreatic and intestinal enzyme complex for the treatment of malfunctioning, or absent amylases enzymes activity but not deficiency, in association with or without excess saccharides in the body. | 2009-12-24 |
20090317372 | SMALL MOLECULES FOR THE REDUCTION OF HIGH BLOOD GLUCOSE LEVEL - Embodiments of the present invention include the in vivo use of a family of heterocyclic compounds containing a quaternary ammonium group as exemplified by the thioxanthone and thioxanthene compounds [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride, or CCcompound1, N,N,-diethyl-N-methyl-2-[9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide, or CCcompound3, and N,N,N-trimethyl-3-(9H-thioxanthen-9-ylidene)-propane-1-aminium iodide, or CCcompound19 to reduce higher than normal blood glucose level within or close to the normal range in subjects with insulin resistance, hyperglycemia, and diabetes thereby also reducing or preventing associated diseases, complications, and pathological states. | 2009-12-24 |
20090317373 | Inhibition of the Anti-FVIII Immune Response - The invention relates to a compound capable of inhibiting the endocytosis of FVIII (factor VIII) by immune system cells capable of endocytosing the antigen and to the therapeutic use of such a compound for the manufacture of a medicament for use in the treatment of hemophiliacs in order to reduce the immunogenicity of FVIII and/or increase the half-life of FVIII. | 2009-12-24 |
20090317374 | COMPOSITION CONTAINING ARAZYME FOR THE PREVENTION AND TREATMENT OF CANCER - The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by | 2009-12-24 |
20090317375 | VON WILLEBRAND FACTOR (VWF) INHIBITORS FOR TREATMENT OR PREVENTION OF INFARCTION - This invention relates to methods for treating or preventing an infarction by administering to a patient in need thereof a compound capable of suppressing the expression or activity of the von Willebrand Factor (VWF). Thus, the invention relates to the use of a pharmaceutically effective amount of a VWF inhibitor, such as ADAMTS13, for the preparation of a medicament for treating conditions known to involve infarction to reduce or eliminate the symptoms and effect of an infarction. | 2009-12-24 |
20090317376 | Compositions And Methods For Lipo Modeling - Methods for lipomodeling by peripherally administering a modulator of a Y receptor are provided. Methods may comprise reduction of a fat depot by administering a Y receptor antagonist proximally and/or directly to the site of the fat depot. Other methods comprise increasing or stabilizing a fat depot or fat graft by administering a Y receptor agonist proximally and/or directly to the site of the fat depot or fat graft. Also provided are methods for stimulating wound healing by administering a Y receptor agonist proximally to a wound site. | 2009-12-24 |
20090317377 | Therapy procedure for drug delivery for trigeminal pain - The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region. | 2009-12-24 |
20090317378 | Antimicrobial composition and uses thereof - A composition for prophylactic and/or therapeutic medicinal applications, or plant protection applications, in particular for the control of microorganisms, either planktonic or organized in biofilms. The composition includes at least one ion selected from hypohalite, at least one compound selected from lactoferrin, lactoferrin peptide, lysozyme, immunoglobulins or a combination thereof, optionally hypothiocyanite, and optionally at least one growth factor. | 2009-12-24 |
20090317379 | AUTOPHILIC ANTIBODIES AND METHOD OF MAKING THE SAME - Antibodies having noncovalent, autophilic properties are disclosed. The autophilic antibodies are derived from antibodies conjugated with an autophilic peptide. Such autophilic antibodies can promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Compositions containing the antibodies, and methods of making and using the antibodies are also disclosed. | 2009-12-24 |
20090317380 | USE OF PRION CONVERSION MODULATING AGENTS - The use of Apolipoprotein B, Apoliporpotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications in prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathies and other prion diseases. | 2009-12-24 |
20090317381 | CLEARANCE OF ABNORMAL IGA1 IN IGA1 DEPOSITION DISEASES - The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof. | 2009-12-24 |
20090317382 | USE OF EFFECTOR-FUNCTION-DEFICIENT ANTIBODIES FOR TREATMENT OF AUTO-IMMUNE DISEASES - The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen. | 2009-12-24 |
20090317383 | CANCER TREATMENT METHOD - The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound. | 2009-12-24 |
20090317384 | Methods of using death receptor ligands and cd20 antibodies - Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies. | 2009-12-24 |
20090317385 | Methods Using Immunomodulatory Compounds for Modulating Level of CD59 - Provided herein are methods of treating, preventing or managing disorders associated with low CD59 levels. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino- | 2009-12-24 |
20090317386 | Transcription Infidelity, Detection and Uses Thereof - The present invention relates to the identification of a novel mechanism of transcription infidelity in cells. The invention provides compositions and methods to detect the level of transcript ion infidelity in a sample, as well as the use thereof, e.g., for therapeutic, diagnostic, pharmacogenomic or drug design. As will be disclosed, the invention is particularly suited for detecting, monitoring or treating proliferative cell disorders, for the design and/or screening of drugs, for patient or disease profiling, prediction of disease severity and evaluation of drug efficacy. | 2009-12-24 |
20090317387 | TREATMENT OF METASTATIC BREAST CANCER - The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel. | 2009-12-24 |
20090317388 | Tl1a in treatment of disease - Methods of modulating TL1A for the treatment of disease are disclosed. | 2009-12-24 |
20090317389 | FUSION MOLECULES AND METHODS FOR TREATMENT OF IMMUNE DISEASES - The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The invention provides methods for the suppression of type I hypersensitive (i.e., IgE-mediated) allergic conditions, methods for the prevention of anaphylactic responses that occur as a result of traditional peptide immunotherapies for allergic and autoimmune disorders, and provides novel methods for the treatment of autoimmune conditions, where the methods have reduced risk of triggering an anaphylactic response. The invention provides novel therapeutic approaches for the treatment of allergic responses, including the prevention of anaphylactic response that can occur from environmental allergen exposure. The invention also provides methods for the treatment of autoimmune disorders such as multiple sclerosis, autoimmune type I diabetes mellitus, and rheumatoid arthritis. The invention also provides methods for preventing anaphylactic response during traditional antigen therapies. | 2009-12-24 |
20090317390 | NOVEL TISSUE FACTOR TARGETED ANTIBODIES AS ANTICOAGULANTS - This invention relates to novel antibodies that bind with greater affinity to the factor VIIa/tissue factor (FVIIa/TF) complex than to tissue factor (TF) alone, do not compete for binding to TF with FVII and FX, and inhibit FX activation. The antibodies bind at the site of injury and prevent the initiation of thrombosis. The antibodies can be used to treat a variety of thrombotic conditions including, but not limited to, deep vein thrombosis, disseminated intravascular coagulation, and acute coronary syndrome. | 2009-12-24 |
20090317391 | Cancer Related Genes (PTPE) - This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the tm-PTPε gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the tm-PTPε gene. | 2009-12-24 |
20090317392 | METHOD OF DIAGNOSING SMALL CELL LUNG CANCER - Objective methods for detecting and diagnosing small cell lung cancer (SCLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that discriminates between SCLC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of an SCLC-associated gene that distinguishes two major histological types of lung cancer, non-small cell lung cancer (NSCLC) and SCLC. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of small cell lung cancer, methods of treating small cell lung cancer and method for vaccinating a subject against small cell lung cancer. Furthermore, the present invention provides chemotherapy resistant lung cancer- or SCLC-associated genes as diagnostic markers and/or molecular targets for therapeutic agent for these cancers. These genes are up-regulated in chemoresistant lung cancer or SCLC. Accordingly, chemoresistant lung cancer or SCLC can be predicted using expression level of the genes as diagnostic markers. As the result, any adverse effects caused by ineffective chemotherapy can be avoided, and more suitable and effective therapeutic strategy can be selected. | 2009-12-24 |
20090317393 | METHOD OF MODIFYING GLUCOSE ACTIVITY USING POLYPEPTIDES SELECTIVELY EXPRESSED IN FAT TISSUE - Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition. | 2009-12-24 |
20090317394 | VASCULAR ENDOTHELIAL GROWTH FACTOR-2 - The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides. | 2009-12-24 |
20090317395 | Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP) - The present invention relates to a new antimicrobial peptide, comprising the amino acid sequence of human galanin message associated peptide (GMAP) or a homolog, ortholog, chemically modified variant or antimicrobially active variant thereof, and respective uses thereof, particular in the topical treatment of antimicrobial diseases. | 2009-12-24 |
20090317396 | ANTIBODY SPECIFICALLY BINDING TO DR5 AND COMPOSITION FOR PREVENTING OR TREATING CANCERS COMPRISING THE SAME - The present invention provides an antibody specifically binding to death receptor 5 (DR5), which is selected from the group consisting of: an antibody comprising a heavy chain variable region (V | 2009-12-24 |
20090317397 | Soluble CTLA4 mutant molecules and uses thereof - The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions. | 2009-12-24 |
20090317398 | MAMMALIAN CX3C CHEMOKINE ANTIBODIES - Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 2009-12-24 |
20090317399 | Uses and compositions for treatment of CROHN'S disease - The invention provides methods, uses and compositions for the treatment of Crohn's disease. The invention describes methods and uses for treating Crohn's disease, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to induce and maintain remission of Crohn's disease in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of Crohn's disease in a subject. | 2009-12-24 |
20090317400 | Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof - This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic. | 2009-12-24 |
20090317401 | Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 - The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production | 2009-12-24 |
20090317402 | ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions. | 2009-12-24 |
20090317403 | Use of CSF-1 Inhibitors - Disclosed is the use of inhibitors of CSF-1 activity for preparing a medicament for the treatment of tumor diseases. | 2009-12-24 |
20090317404 | REDUCTION AND PREVENTION OF CELL-ASSOCIATED HIV TRANSEPITHELIAL MIGRATION, MICROBIDES AND OTHER FORMULATIONS AND METHODS - A vaginal microbicide including scFv-type antibodies reduces or prevents transepithelial HIV transmission. As the antibodies, anti-CD 18 and/or anti-CD 11 antibodies (of the scFv type) are used. Preferably, anti-ICAM antibody also is used. The antibodies may be delivered to the to-be-protected epithelium using a bacterial delivery system such as a | 2009-12-24 |
20090317405 | ANTIBODY AND USES THEREOF - Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis. | 2009-12-24 |
20090317406 | Phosphorylation of tau by abl - Methods of diagnosing a tauopathy and predicting whether a subject will develop a tauopathy are provided. Also provided are antibody preparations that specifically bind to tau phosphorylated at tyr394 and/or tyr310. Methods of inhibiting tau phosphorylation in a cell and methods of treating a subject having a tauopathy are additionally provided. Methods of treating a subject at risk for a tauopathy are also provided. Additionally, non-human mammals comprising a transgene encoding an abl tyrosine kinase are provided. Also provided are methods of evaluating whether a compound inhibits development of a tauopathy. | 2009-12-24 |
20090317407 | AUGMENTATION OF IMMUNE RESPONSE TO CANCER VACCINE - Methods are disclosed for stimulating an immune response against a target antigen, such as one or more tumor associated antigens. In particular examples the method includes reducing the number of CD4+ T cells in a subject after the subject receives a first dose of an immunogenic composition that includes the target antigen (such as a cancer vaccine), wherein the subject has a tumor that expresses the target antigen. The subject is administered a second dose of the immunogenic composition, thereby stimulating an immune response against the target antigen. In some examples the method also includes administering to the subject peripheral blood mononuclear cells (PBMCs) (for example a population of PBMCs depleted of CD25 cells, CD81 cells, CD134 | 2009-12-24 |
20090317408 | LIGAND CONJUGATED THERMOTHERAPY SUSCEPTORS AND METHODS FOR PREPARING SAME - Magnetic nanoparticles exhibiting enhanced heating ability in thermotherapeutic applications are described, as are several strategies to conjugate such nanoparticles. Methods for using conjugated nanoparticles are also provided. | 2009-12-24 |
20090317409 | Antibodies for ubiquitinated proteins - The invention relates to particular ubiquitination epitopes, antibodies that specifically recognize and bind to ubiquitinated proteins and peptides (particularly after the ubiquitin is removed by proteolytic cleavage) and to methods of using these epitopes and antibodies. | 2009-12-24 |
20090317410 | USE OF ZWITTERIONIC POLYSACCHARIDES FOR THE SPECIFIC MODULATION OF IMMUNE PROCESSES - The invention relates to three-dimensional molecular structure determination of polymers, three-dimensional computer molecular modeling, rational drug design, and immunomodulatory polymers. In particular the invention is directed to immunomodulatory polymers, as well as to methods for designing, selecting, and screening therapeutic agents having immunomodulatory activity. | 2009-12-24 |
20090317411 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES SPECIFIC TO GLOBO H AND SSEA3 AND USES THEREOF IN CANCER TREATMENT - An immune composition containing Globo H or its fragment (e.g., SSEA3) and an adjuvant, e.g., α-GalCer, for eliciting immune responses against Globo H or its fragment and uses thereof in cancer treatment. Also disclosed is a method of treating cancer by inhibiting the activity of one of FUT1 and FUT2, both of which involve in Globo H biosynthesis. | 2009-12-24 |
20090317412 | Induction of an immune response against streptococcus pneumoniae polyaccharides - The present invention provides conjugates of pan DR binding peptides with | 2009-12-24 |
20090317413 | DETECTION OF HUMAN PLATELET ANTIGEN (HPA) ANTIBODIES - This invention relates to recombinant GPIIIa molecules that lack the ligand binding βA domain and bind to HPA-1 antibodies in monomeric form. These GPIIIa molecules can be recombinantly expressed at high levels and may be useful, for example, in the detection of HPA-1 antibodies. Such detection may be useful, for example, in the diagnosis and therapy of HPA antibody disorders such as Neonatal Alloimmune Immune Thrombocytpenia (NAIT), Post Transfusion Purpura (PTP) and Platelet Refractoriness (PR). | 2009-12-24 |
20090317414 | CANCER VACCINE COMPRISING A MUCIN 1 (MUC1) T CELL EPITOPE-DERIVED PEPTIDE - A cancer vaccine, and a composition for the ex vivo priming of dendritic cells, is disclosed which comprises a MUC1 T cell epitope-derived peptide or peptide analogue capable of provoking a cytotoxic T cell immune response. Particular MUC1 T cell epitope-derived peptides disclosed include TTAPPVHGL, STAPPVHGL, STAPPAHGL, TTAPPAHGV and SAPDTYPAL. | 2009-12-24 |
20090317415 | HPV VACCINE COMPRISING PEPTIDES FROM HOST CELL PROTEINS - The present invention relates to an immunogenic composition for a human papillomavirus (HPV) vaccine that comprises BAX peptides from BAX host cell proteins and more particularly, a vaccine including those peptides that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The BAX peptides comprise fragments of BAX host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as BAX peptide/HLA complexes and their use in a tumour-specific vaccine. | 2009-12-24 |
20090317416 | INDUCTION OF IMMUNE RESPONSES TO ISOASPARTYL-MODIFIED ANTIGENS - The present invention is directed to a method of enhancing the immune response of a patient relative to the normal immune response, by administering isoaspartyl-modified proteins, peptides, or cells, to a patient. The present invention is also directed to vaccines containing the isoaspartyl-modified proteins, peptides, or cells, as well as antibodies reactive with the isoaspartyl-modified proteins, peptides, or cells. | 2009-12-24 |
20090317417 | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof - A method of reducing the cellular immune response and/or toxicity of AAV-mediated delivery is described. The method provides for masking or ablating a RxxR motif which induces T-cells, and which is located on select AAV capsids. The method further provides for reducing or eliminating heparin binding to an AAV. Also provided are compositions containing modified AAV capsids and methods of using same. | 2009-12-24 |
20090317418 | VACCINES AND METHODS FOR PREVENTION AND TREATMENT OF DRUG-RESISTANT HIV-1 AND HEPATITIS B VIRUS - The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved. | 2009-12-24 |
20090317419 | Tetramers - The present invention relates, in general to human immunodeficiency virus (HIV), and, in particular, to B cell tetramers and to methods of using same for diagnosis, disease monitoring and vaccine development. | 2009-12-24 |
20090317420 | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae - The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B | 2009-12-24 |
20090317421 | COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL BACTERIUM PROTEINS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2009-12-24 |
20090317422 | USE OF PPD FOR THE ADJUVANTATION OF A NUCLEIC ACID VACCINE - The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines. | 2009-12-24 |
20090317423 | PCV2 MYCOPLASMA HYOPNEUMONIAE IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein. | 2009-12-24 |
20090317424 | Oral vaccines - This invention features a composition that includes a multiple-cell organism for use as food for an aquatic animal (e.g., a fish or a shrimp), and a single-cell organism fed to, and as a result, bioencapsulated by, the multiple-cell organism. The single-cell organism has been transformed to express a recombinant antigen that induces an immune response in the aquatic animal. | 2009-12-24 |
20090317425 | REFRIGERATOR-TEMPERATURE STABLE INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided. | 2009-12-24 |
20090317426 | METHOD FOR TREATING KNEE JOINT PAIN CAUSED BY SAPHENOUS NERVE ENTRAPMENT - A method using a pharmaceutical composition comprising botulinum toxin and a pharmacologically acceptable carrier to treat pain in the knee joint caused by saphenous nerve entrapment. The composition of the present invention is for subcutaneous injection above the medial side of the knee. | 2009-12-24 |
20090317427 | Zwitterionic Polysaccharides for Promotion of Immune System Maturation and Health - Certain zwitterionic polysaccharides, including those naturally expressed by commensal | 2009-12-24 |
20090317428 | Immunogenic T-Helper Epitopes From Human Tumour Antigens and Immunotherapeutic Methods Using Said Epitopes - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 2009-12-24 |
20090317429 | Aloe vera cotton swab tips - This paper describes how implementing an | 2009-12-24 |
20090317430 | COSMETIC COMPOSITION FOR LIGHTENING OR UNIFYING THE COMPLEXION - Cosmetic composition for lightening or unifying the complexion The present invention relates to a composition comprising, in a physiologically acceptable medium, concave or annular particles, especially in the form of hollow sphere portions, the said particles comprising a matrix that is coloured in the bulk. | 2009-12-24 |
20090317431 | PEELING CAPSULES - A cosmetic peeling preparation which comprises a plurality of capsules. A capsule comprises a casing and a filling. The casing material is solid at 25° C. and selected from cosmetically conventional lipids, waxes, emulsifiers, natural polymers, synthetic polymers, and mixtures thereof. The filling comprises an oil or lipid mixture having a viscosity at 25° C. of from 3 to 50,000 mPas and one or more solid substances having an abrasive effect. | 2009-12-24 |
20090317432 | FELT-TIP PEN FOR MAKING UP OR CARING FOR NAILS, SKIN, LIPS EYELASHES OR TEETH - The present invention relates to an assembly for the application of a nail varnish composition or a composition for making up and/or caring for keratin materials chosen from the skin, the lips and the eyelashes, or the teeth, comprising:
| 2009-12-24 |
20090317433 | Liquid Pesticide Composition Containing N-Phenylsemicarbazone Pesticide Compounds - Liquid pesticide composition containing N-phenylsemicarbazone pesticide compounds | 2009-12-24 |
20090317434 | Preparation method for antibacterial nanocomposite fiber materials containing organic intermediates or free-radical scavengers - The invention relates to a novel preparation method for antibacterial nano metal composite fiber materials containing organic intermediate or free radical scavengers. The technology for the invention mainly uses γ-ray radiation to a solution mixture containing PAA (polyacrylic acid intermediate) or IPA (Isopropyl alcohol free radical scavenger) and silver nitrate solution to induce crosslinking or grafting on Nylon or PET fiber surface and produce nanocomposite fiber products with excellent antibacterial ability. The main reaction mechanism is through PAA or IPA as additives to assist silver particles in adhering firmly onto Nylon or PET fiber surface. With good thermal stability and chemical stability silver is considered as an excellent inorganic antibacterial agent. It can easily react with enzyme-protein molecules in bacteria and achieve sterilization effect by destructing cell surface and killing the bacteria. The antibacterial testing report indicates Nylon and PET fibers containing nano silver have excellent antibacterial ability. The invented product can be used for functional textiles for medical applications, personal products and manufacturing environment. | 2009-12-24 |
20090317435 | METHODS FOR PROCESSING SUBSTRATES HAVING AN ANTIMICROBIAL COATING - Methods for processing substrate surfaces carrying coatings comprising a metal are disclosed. The methods involve providing a substrate surface having a coating comprising a metal, and exposing the substrate surface to a mixture including an oxidizing agent and an anion. | 2009-12-24 |
20090317436 | COMPUTER DEVICES AND ACCESSORIES - Computer devices ( | 2009-12-24 |
20090317437 | CELLULOSE GEL FORMULATIONS - The invention relates to dispersible cellulose powder compositions comprising non-seed cellulose powder derived from algae, fungi or tunicates, which compositions are useful in a variety of products such as food products, pharmaceuticals, cosmetics, paints, biocompatible materials for artificial tissue engineering and implantable biomaterials and relates to methods for preparing non-seed cellulose powder compositions. | 2009-12-24 |
20090317438 | WHOLE BLOOD-DERIVED COAGULUM DEVICE FOR TREATING BONE DEFECTS - Whole blood-derived coagulum devices are described for use in treating bone defects. | 2009-12-24 |
20090317439 | Cell Preparations for Extemporaneous Use, Useful for Healing and Rejuvenation In Vivo - The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides compositions comprising plasma or platelet-rich plasma alone or in combination with cell preparations for use in tissue regeneration and bone regeneration and pain reduction. | 2009-12-24 |
20090317440 | ANTI-MITOTIC ANTI-PROLIFERATIVE COMPOUNDS - Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof. | 2009-12-24 |